Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another \u201cFirst Cycle\u201d FDA Approval for an Abbreviated New Drug Application (ANDA), Dexmedetomidine Hydrochloride Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq\/mL","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Acella Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Milla Pharmaceuticals

    Menu

    Milla Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Milla Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL

              Details:

              Sodium Acetate-generic Injection 4 mEq/mL is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.

              Lead Product(s): Sodium Acetate

              Therapeutic Area: Nephrology Product Name: Sodium Acetate-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Woodward Pharma Services

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Milla Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup

              Details:

              Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.

              Lead Product(s): Pyridostigmine

              Therapeutic Area: Immunology Product Name: Mestinon-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Acella Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Milla Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another “First Cycle” FDA Approval for an Abbreviated New Drug Application (ANDA), Dexmedetomidine Hy...

              Details:

              Dexmedetomidine hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.

              Lead Product(s): Dexmedetomidine Hydrochloride

              Therapeutic Area: Neurology Product Name: Precedex-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Milla Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma Group

              Details:

              Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.

              Lead Product(s): Pyridostigmine

              Therapeutic Area: Immunology Product Name: Pyridostigmine Bromide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Alter Pharma group

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY